Despite these limitations, our discovery of pCTS-L–neutralizing mAbs capable of disrupting its interaction with TLR4 and RAGE receptors to attenuate dysregulated inflammation has suggested an exciting possibility of developing antibody strategies to fight against lethal sepsis. This evidence concerns the gene TLR4 and Sepsis.